Rate of 3% Hypertonic Saline for Lowering ICP in Pediatrics
For pediatric patients with elevated intracranial pressure, administer 3% hypertonic saline as a continuous infusion targeting serum sodium of 145-155 mmol/L, or as bolus doses of 5 mL/kg over 5 minutes to 2 hours when acute ICP reduction is needed. 1
Administration Methods
Continuous Infusion (Preferred for Sustained Control)
- Target serum sodium: 145-155 mmol/L 1
- Infusion rates typically range from 0.5-2 mL/kg/hr after initial bolus 2
- This approach has been safely used for mean duration of 7.6 days in pediatric traumatic brain injury 3
- Studies demonstrate sustained ICP control without significant adverse effects even with prolonged use 1
Bolus Therapy (For Acute ICP Elevation)
- Dose: 5 mL/kg of 3% saline 4
- Administer over 5 minutes to 2 hours 2
- Expected effect: ICP reduction of approximately 5 mmHg lasting 3 hours 4
- The "53-53 rule" applies: 5 mL/kg of 3% HTS decreases ICP by at least 5 mmHg for 3 hours 4
- CPP increases by approximately 4 mmHg within 1 hour 4
Clinical Algorithm
Step 1: Initial Assessment
- Confirm elevated ICP requiring osmotic therapy
- Check baseline serum sodium (must be <155 mmol/L before administration) 1
Step 2: Choose Administration Strategy
- For acute ICP crisis: Bolus 5 mL/kg over 5-30 minutes
- For sustained ICP control: Initiate continuous infusion at 0.5-1 mL/kg/hr after loading dose
Step 3: Monitoring Protocol
- Measure serum sodium within 6 hours of bolus administration 1
- For continuous infusions, monitor sodium every 6-12 hours
- Do not re-administer until serum sodium <155 mmol/L 1
- Track ICP and CPP continuously if monitoring available
Safety Profile
The evidence strongly supports safety in pediatric populations:
- No osmotic demyelination syndrome documented in 68 children receiving 3% infusions, including autopsy and MRI evidence 1
- Mean highest serum sodium of 170.7 mmol/L tolerated without adverse effects 1, 3
- Maximum osmolarity of 431 mOsm/L documented in individual patients without complications 1
- Two cases of acute renal failure occurred concurrent with sepsis/multisystem organ dysfunction, both recovered fully 3
Critical Caveats
Pre-bolus sodium does NOT predict effectiveness: The magnitude of ICP reduction is not correlated with baseline serum sodium concentration 4. This means 3% saline remains effective even at higher baseline sodium levels (though safety monitoring remains essential).
Interhemispheric discordance matters: Patients with bihemispheric or unihemispheric rcSO2 <60% with interhemispheric discordance >10% show the greatest positive response but require more frequent dosing 5.
Therapeutic response timing: Significant 15% improvement in cerebral oxygenation occurs within 1.2-2.1 minutes of infusion, particularly in subdural hematomas 5.
Comparison to Mannitol
Recent high-quality pediatric studies show:
- 3% HTS superior to 20% mannitol for achieving target ICP <20 mmHg (79.3% vs 53.6%) 6
- Greater ICP reduction: -14.3 mmHg vs -5.4 mmHg with mannitol 6
- Higher CPP elevation: 15.4 mmHg vs 6 mmHg 6
- Shorter mechanical ventilation duration and PICU stay 6
However, the most recent 2025 multicenter cohort study found no difference in mortality or functional outcomes between HTS and mannitol 7, and a 2025 meta-analysis confirmed no significant differences in mortality, ICP changes, or secondary outcomes 8.
Practical Implementation
Route of administration: Both central and peripheral IV access are safe 9. While central access is traditionally preferred, peripheral administration is acceptable with proper monitoring for phlebitis and extravasation 9.
Storage considerations: Institutional protocols should address regulatory requirements for safe storage in patient care areas with appropriate safeguards 9.
The evidence base is Grade A for ICP reduction efficacy but does not demonstrate survival benefit or improved neurological outcomes 1. Use 3% HTS as part of a comprehensive ICP management algorithm, not as monotherapy.